
    
      In Stage 1 of the study, all eligible AML patients with demonstrated MCL-1 dependence of ≥
      30% by mitochondrial profiling in bone marrow will receive treatment with ACM.

      In Stage 2, all eligible AML patients with demonstrated MCL-1 dependence of ≥ 30% by
      mitochondrial profiling in bone marrow will be randomized 1:1 to receive either treatment
      with ACM or CM.
    
  